CD47 and neoplasm: We found that CD47 × PD‐L1 BisAb treatment augmented CD8+ T cell responses in tumors, which resulted in enhanced tumor control. Compared with anti‐PD‐L1 treatment, dual CD47 and PD‐L1 blockade promoted greater numbers of antigen‐specific tumor‐resident CD8+ T cells that exhibited increased cytokine production.